Compare GYRE & VTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GYRE | VTS |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.1M | 847.3M |
| IPO Year | 2004 | 2022 |
| Metric | GYRE | VTS |
|---|---|---|
| Price | $8.33 | $19.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $17.00 | ★ $26.50 |
| AVG Volume (30 Days) | 58.7K | ★ 332.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.34% |
| EPS Growth | 103.55 | ★ 187.67 |
| EPS | 0.04 | ★ 0.67 |
| Revenue | $275,000.00 | ★ $241,998,000.00 |
| Revenue This Year | $11.59 | $29.38 |
| Revenue Next Year | $26.31 | N/A |
| P/E Ratio | $214.38 | ★ $29.59 |
| Revenue Growth | N/A | ★ 3.46 |
| 52 Week Low | $6.11 | $18.85 |
| 52 Week High | $13.47 | $27.15 |
| Indicator | GYRE | VTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 36.64 |
| Support Level | $6.94 | $19.21 |
| Resistance Level | $9.31 | $20.24 |
| Average True Range (ATR) | 0.37 | 0.71 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 48.89 | 4.03 |
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.